Olaparib-Abiraterone in Biomarker-Selected mCRPC Tops Each Agent Alone

(MedPage Today) -- SAN FRANCISCO -- Combining a PARP inhibitor with an androgen receptor pathway inhibitor as first-line therapy for biomarker-selected patients with metastatic castration-resistant prostate cancer (mCRPC) significantly improved...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news